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A B S T R A C T
The pharmacoresistance to antiepileptic drugs (AEDs) remains a major unsolved therapeutic need. The over-
expression of multidrug transporters, as the P-glycoprotein (P-gp), at the level of the blood-brain barrier of
epileptic patients has been suggested as a key mechanism underlying the refractory epilepsy. Thus, efforts have
been made to search for therapeutically useful P-gp inhibitors. Herein, the strategy of flavonoid/AED combined
therapy was exploited as a possible approach to overcome the P-gp-mediated pharmacoresistance. For this
purpose, several in vitro studies were performed using Madin-Darby canine kidney II (MDCK II) cells and those
transfected with the human multidrug resistance-1 (MDR1) gene, overexpressing the P-gp (MDCK-MDR1).
Overall, the results showed that baicalein, (−)-epigallocatechin gallate, kaempferol, quercetin and silymarin, at
200 μM, produced a marked increase on the intracellular accumulation of rhodamine 123 in MDCK-MDR1 cells,
potentially through inhibiting the P-gp activity. In addition, with the exception of lamotrigine, all other AEDs
tested (phenytoin, carbamazepine and oxcarbazepine) and their active metabolites (carbamazepine-10,11-ep-
oxide and licarbazepine) demonstrated to be P-gp substrates. Furthermore, the most promising flavonoids as P-
gp inhibitors promoted a significant increase on the intracellular accumulation of the AEDs (excluding lamo-
trigine) and their active metabolites in MDCK-MDR1 cells, evidencing to be important drug candidates to reverse
the AED-resistance. Thus, the co-administration of AEDs with baicalein, (−)-epigallocatechin gallate, kaemp-
ferol, quercetin and silymarin should continue to be explored as adjuvant therapy for refractory epilepsy.
List of chemical compounds studied in this article:
Baicalein (PubChem CID: 5,281,605); Carbamazepine (PubChem CID: 2554); Carbamazepine 10,11-epoxide
(PubChem CID: 2555); (−)-Epigallocatechin gallate (PubChem CID: 65064); Kaempferol (PubChem CID:
5280863); Lamotrigine (PubChem CID: 3878); Licarbazepine (PubChem CID: 114709); Oxcarbazepine
(PubChem CID: 34312); Phenytoin (PubChem CID: 1775); Silymarin (PubChem CID: 7073228); Quercetin
(PubChem CID: 5280343); Verapamil (PubChem CID: 2520).
1. Introduction
Despite the clinical availability of more than twenty antiepileptic
drugs (AEDs) with different pharmacokinetic profiles, mechanisms of
action and potential for drug interactions, the development of drug-
resistant epilepsy remains as a major unresolved problem, affecting
30–40% of patients (Baulac et al., 2015; Franco, French, & Perucca,
2016; Ventola, 2014). Although several pathomechanisms have been
advocated to explain the drug resistance to AEDs, two major hypotheses
have gained emphasis: the target hypothesis and the multidrug trans-
porter hypothesis (Löscher, Klitgaard, Twyman, & Schmidt, 2013;
Rogawski, 2013; Wang, Wang, Liu, &Ma, 2016). The former postulates
that AEDs lose efficacy due to changes in the structure/functionality of
their target ion channels and neurotransmitter receptors; while the
multidrug transporter hypothesis suggests an overexpression of multi-
drug efflux transporters such as P-glycoprotein (P-gp) in brain capillary
endothelial cells, restricting AEDs penetration into the brain tissue of
non-responsive epileptic patients (Ferreira, Pousinho, Fortuna,
Falcão, & Alves, 2015; Gidal, 2014; Xiong, Mao, & Liu, 2015). This hy-
pothesis has been supported by important clinical findings that de-
monstrated a greater expression of P-gp in patients with recurrent sei-
zures (drug-resistant patients) than in those who have been seizure-free
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